CEO, A. Stotz Investment Research

Dr. Andrew Stotz, CFA

Quantamental Investing to beat Benchmarks

A. Stotz Investment Research

We pick stocks. We construct portfolios. All our effort is focused on how to better pick stocks and construct portfolios. We serve fund management companies, family offices, and high net worth individuals.

Equity Bottom-Up

We maintained a HOLD recommendation on DOD and an unchanged target price of Bt13.30, implying an upside of 2% from the current price. We derive our target price from the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:
<ul>
<li>Network marketing creates a new sales channel with tremendous growth potential</li>
<li>High R&amp;D spending and hemp legalization help to remain competitive</li>
<li>Proposal to cease its loss-making cosmetics segment should bring profit on track</li>
</ul>
Interim: Strong performance of its core segment supplements in 1Q21 was partly dragged by disappointing cosmetics and network marketing segment results. The resulting decision to exit cosmetics operations has led to slight revisions in our forecast.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

We maintained a HOLD recommendation on DOD and an unchanged target price of Bt13.30, implying an upside of 2% from the current price. We derive our target price from the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:

Network marketing creates a new sales channel with tremendous growth potential
High R&amp;D spending and hemp legalization help to remain competitive
Proposal to cease its loss-making cosmetics segment should bring profit on track

Interim: Strong performance of its core segment supplements in 1Q21 was partly dragged by disappointing cosmetics and network marketing segment results. The resulting decision to exit cosmetics operations has led to slight revisions in our forecast.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

DOD: Failed Investment in Cosmetics Requires New Strategy

We change our recommendation to a HOLD from BUY after DOD showed a strong price rally. But we increase our target price to Bt13.30 from Bt10.70, which is 2% above the current market price. We derive our target price from the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:
<ul>
<li>Network marketing creates a new sales channel with tremendous growth potential</li>
<li>Recent acquisition expands cosmetics manufacturing capacity</li>
<li>High R&amp;D spending and hemp legalization help to remain competitive</li>
</ul>
Interim: Apart from its goodwill write-down causing a net loss, DOD continues to deliver good operating results, supported by its strong food supplement segment. The 4Q20 results confirm our growth expectations, but we believe that they are already priced in.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

We change our recommendation to a HOLD from BUY after DOD showed a strong price rally. But we increase our target price to Bt13.30 from Bt10.70, which is 2% above the current market price. We derive our target price from the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:

Network marketing creates a new sales channel with tremendous growth potential
Recent acquisition expands cosmetics manufacturing capacity
High R&amp;D spending and hemp legalization help to remain competitive

Interim: Apart from its goodwill write-down causing a net loss, DOD continues to deliver good operating results, supported by its strong food supplement segment. The 4Q20 results confirm our growth expectations, but we believe that they are already priced in.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

DOD: Recent Bullish Rally Overestimates Hemp Hype

We keep our BUY recommendation on DOD based on our target price of Bt10.70, implying an upside of 18% from the current price. We derive our target price from the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:
<ul>
<li>Network marketing creates a new sales channel with tremendous growth potential</li>
<li>Recent acquisition expands cosmetics manufacturing capacity</li>
<li>Significant R&amp;D spending necessary to remain competitive</li>
</ul>
Interim: DOD continues to deliver strong results, and revenue was up 80% YoY. The results were in line with our expectations. The cosmetics segment’s revenue was lower than expected, but this was offset by better performance in food supplements.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

We keep our BUY recommendation on DOD based on our target price of Bt10.70, implying an upside of 18% from the current price. We derive our target price from the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:

Network marketing creates a new sales channel with tremendous growth potential
Recent acquisition expands cosmetics manufacturing capacity
Significant R&amp;D spending necessary to remain competitive

Interim: DOD continues to deliver strong results, and revenue was up 80% YoY. The results were in line with our expectations. The cosmetics segment’s revenue was lower than expected, but this was offset by better performance in food supplements.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions. 

DOD: More to Come in Beauty Products and Network Marketing

ASEAN Insight Provider, CrossASEAN Research

Angus Mackintosh

ASEAN Insight Provider

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Cross Asset Strategy

<div class="content-highlight">
Corrigenda: There is an error in this Insight. Please note the correction.
Correction: The <a href="https://www.smartkarma.com/insights/singapore-sti-macro-bear-pressure-mounting-with-tactical-relief-from-2-400" target="_blank" data-smartkarma-citation="insights:42932" rel="noopener">Singapore STI Macro Bear Pressure Mounting with Tactical Relief from 2,400</a> Insight is improperly attributed to Thomas Monaco. That Insight was published by <a href="https://www.smartkarma.com/profiles/thomas-schroeder" target="_blank" data-smartkarma-citation="accounts:381" rel="noopener">Thomas Schroeder</a>.
</div>
<hr>
<div class="content-highlight">
The week that was in ASEAN@Smartkarma is filled with another eclectic mix of differentiated, substantive and actionable insights from across South East Asia and includes macro, top-down and thematic pieces, as well as actionable equity bottom-up and credit insights over the past week.
Please find a brief summary below, with a fuller write up in the detailed section. We also include in the detailed section the past week's relevant discussions in <a href="mailto:ASEAN@Smartkarma" target="_blank" rel="noopener">ASEAN@Smartkarma.</a>
</div>
<h3>Equity Bottom-Up Insights</h3>
In <a href="https://www.smartkarma.com/insights/kalbe-farma-klbf-ij-a-nutritional-spin-off" target="_blank" data-smartkarma-citation="insights:42533" rel="noopener">Kalbe Farma (KLBF IJ) - A Nutritional Spin-Off?,</a> CrossASEAN Insight Provider <a href="https://www.smartkarma.com/profiles/angus-mackintosh" target="_blank" data-smartkarma-citation="accounts:937" rel="noopener">Angus Mackintosh</a> revisits South East Asia's largest pharmaceutical company in light of news that the company is considering spinning off its Nutritionals division to raise around US$500m. 
In <a href="https://www.smartkarma.com/insights/link-net-tbk-pt-link-ij-summer-migration-at-last" target="_blank" data-smartkarma-citation="insights:42829" rel="noopener">Link Net Tbk Pt (LINK IJ) - Summer Migration at Last,</a> <a href="https://www.smartkarma.com/profiles/angus-mackintosh" target="_blank" data-smartkarma-citation="accounts:937" rel="noopener">Angus Mackintosh</a> revisits Indonesia's highest quality high-speed broadband provider following a call with managment, which focused on its recent results, as well as the decision to build its own pole infrastructure to carry its fibre.  
In <a href="https://www.smartkarma.com/insights/singtel-make-the-call" target="_blank" data-smartkarma-citation="insights:42900" rel="noopener">SingTel: Make The Call,</a> <a href="https://www.smartkarma.com/profiles/david-blennerhassett" target="_blank" data-smartkarma-citation="accounts:840" rel="noopener">David Blennerhassett</a> zeros in on Singapore's leading telecom provider and finds deep value appearing in the stock.
In <a href="https://www.smartkarma.com/insights/scg-packaging-ipo-initiation-shrink-wrapping" target="_blank" data-smartkarma-citation="insights:42967" rel="noopener">SCG Packaging IPO Initiation: Shrink Wrapping,</a> <a href="https://www.smartkarma.com/profiles/arun-george" target="_blank" data-smartkarma-citation="accounts:1680" rel="noopener">Arun George</a> takes a first look at the upcoming spin-off from <a href="https://www.smartkarma.com/entities/siam-cement-pcl-the" target="_blank" data-smartkarma-citation="entities:2589:1" rel="noopener">Siam Cement (SCC TB)</a> and IPO of SCG Packaging, which will get a lot of investor focus given ist size and share in of the packaging market in SE Asia. 
In <a href="https://www.smartkarma.com/insights/sembcorp-last-chance-before" target="_blank" data-smartkarma-citation="insights:42886" rel="noopener">Sembcorp - Last Chance Before...</a> <a href="https://www.smartkarma.com/profiles/travis-lundy" target="_blank" data-smartkarma-citation="accounts:25" rel="noopener">Travis Lundy</a> looks at the enormously dilutive rights issue and de-merger of Semcorp Marine. 
 In <a href="https://www.smartkarma.com/insights/singapore-sti-macro-bear-pressure-mounting-with-tactical-relief-from-2-400" target="_blank" data-smartkarma-citation="insights:42932" rel="noopener">Singapore STI Macro Bear Pressure Mounting with Tactical Relief from 2,400,</a> technical analysis specialist <a href="https://www.smartkarma.com/profiles/thomas-j-monaco" target="_blank" data-smartkarma-citation="accounts:1716" rel="noopener">Thomas J. Monaco</a> works his technical magic on the <a href="https://www.smartkarma.com/entities/ftse-straits-times-index-sti" target="_blank" data-smartkarma-citation="entities:22902:1" rel="noopener">FTSE Straits Times Index (STI) (STI INDEX).</a>
In <a href="https://www.smartkarma.com/insights/ratch-3q20-earnings-to-improve-from-overseas-performance" target="_blank" data-smartkarma-citation="insights:42789" rel="noopener">RATCH: 3Q20 Earnings to Improve from Overseas Performance</a>, our friend at <a href="https://www.smartkarma.com/companies/country-group" target="_blank" data-smartkarma-citation="companies:965" rel="noopener">Country Group</a> report back on <a href="https://www.smartkarma.com/entities/ratch-group-pcl" target="_blank" data-smartkarma-citation="entities:15338:1" rel="noopener">Ratchaburi Electric (RATCH TB)</a> post its more recent analyst meeting, which left a positive impression.  
In <a href="https://www.smartkarma.com/insights/b-work-good-dividend-yield-makes-an-attractive-investment" target="_blank" data-smartkarma-citation="insights:42782" rel="noopener">B-WORK: Good Dividend Yield Makes an Attractive Investment,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> revisits <a href="https://www.smartkarma.com/entities/bualuang-office-leasehold-real-estate-investment-trust" target="_blank" data-smartkarma-citation="entities:26187:1" rel="noopener">Bualuang Office Leasehold Real Estate Investment Trust (B-WORK TB)</a> and takes a positive view. 
In <a href="https://www.smartkarma.com/insights/rbf-the-excessive-outperformance-may-come-to-a-halt" target="_blank" data-smartkarma-citation="insights:42788" rel="noopener">RBF: The Excessive Outperformance May Come to a Halt,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> upgrades his recommendation on <a href="https://www.smartkarma.com/entities/r-b-food-supply-pcl" target="_blank" data-smartkarma-citation="entities:28949:1" rel="noopener">R&amp;B Food Supply PCL (RBF TB)</a> to HOLD from SELL based on raising his target price of THB9.25 from THB8.70, implying a downside of 9% from the current price. 
In <a href="https://www.smartkarma.com/insights/sti-acquisition-benefits-are-not-fully-priced-in-strong-buy" target="_blank" data-smartkarma-citation="insights:42785" rel="noopener">STI: Acquisition Benefits Are Not Fully Priced In, Strong BUY,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> revisits <a href="https://www.smartkarma.com/entities/stonehenge-inter-pcl" target="_blank" data-smartkarma-citation="entities:27353:1" rel="noopener">Stonehenge Inter (STI TB)</a> with a BUY recommendation based on his target of THB10.10, implying an upside of 31% from the current share price. 
In <a href="https://www.smartkarma.com/insights/dod-strong-performance-deserves-a-re-rating" target="_blank" data-smartkarma-citation="insights:42676" rel="noopener">DOD: Strong Performance Deserves a Re-Rating,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> upgrades his recommendation on <a href="https://www.smartkarma.com/entities/dod-biotech-pcl" target="_blank" data-smartkarma-citation="entities:26179:1" rel="noopener">DOD Biotech PCL (DOD TB)</a> to BUY from HOLD based on raising his target price to Bt10.70 from Bt7.55, implying an upside of 26% from the current price. 
In <a href="https://www.smartkarma.com/insights/vranda-the-calm-before-challenging-times" target="_blank" data-smartkarma-citation="insights:42781" rel="noopener">VRANDA: The Calm Before Challenging Times,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> has a SELL recommendation on <a href="https://www.smartkarma.com/entities/veranda-resort-pcl" target="_blank" data-smartkarma-citation="entities:29176:1" rel="noopener">Veranda Resort PCL (VRANDA TB)</a> based on a target price of THB4.30, implying a downside of 26% from the current share price. 
In <a href="https://www.smartkarma.com/insights/ace-results-are-not-stunning-stay-on-hold" target="_blank" data-smartkarma-citation="insights:42784" rel="noopener">ACE: Results Are Not Stunning, Stay on HOLD,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> upgrades his recommendation on <a href="https://www.smartkarma.com/entities/absolute-clean-energy-pcl" target="_blank" data-smartkarma-citation="entities:29155:1" rel="noopener">Absolute Clean Energy PCL (ACE TB)</a> to HOLD from SELL based on raising his target price to THB3.49 from THB2.64, implying an upside of 8% from the current price. 
In <a href="https://www.smartkarma.com/insights/spa-weak-demand-continues-to-pressure-2h20-earnings" target="_blank" data-smartkarma-citation="insights:42813" rel="noopener">SPA: Weak Demand Continues to Pressure 2H20 Earnings,</a> <a href="https://www.smartkarma.com/profiles/dr-andrew-stotz-cfa" target="_blank" data-smartkarma-citation="accounts:756" rel="noopener">Dr. Andrew Stotz, CFA</a> downgrades <a href="https://www.smartkarma.com/entities/siam-wellness-group-pcl" target="_blank" data-smartkarma-citation="entities:3765:1" rel="noopener">Siam Wellness Group (SPA TB)</a> from BUY to HOLD rating and cut his target price by 31% to THB6.6 to factor in weakening earnings momentum in 2H20. 
In <a href="https://www.smartkarma.com/insights/gunkul-new-60mw-power-plant-to-drive-2h20-earnings" target="_blank" data-smartkarma-citation="insights:42820" rel="noopener">GUNKUL: New 60MW Power Plant to Drive 2H20 Earnings,</a> <a href="https://www.smartkarma.com/companies/country-group" target="_blank" data-smartkarma-citation="companies:965" rel="noopener">Country Group</a> maintain a BUY rating on <a href="https://www.smartkarma.com/entities/gunkul-engineering-pcl" target="_blank" data-smartkarma-citation="entities:15272:1" rel="noopener">Gunkul Engineering (GUNKUL TB)</a> with a target price of THB3.24 derived using DCF method (WACC 7.8% and TG 1%) implying 11.4x FY20E PER or 0.5x relative PER to Thai utility sector. 
<h3>Sector and Thematic Insights</h3>
In <a href="https://www.smartkarma.com/insights/telecom-review-sept-2020-ais-and-asiasoft-get-aggressive-on-gaming" target="_blank" data-smartkarma-citation="insights:41022" rel="noopener">Telecom Review (Sept 2020): AIS and AsiaSoft Get Aggressive on Gaming,</a> our Thai guru <a href="https://www.smartkarma.com/profiles/athaporn-arayasantiparb-cfa" target="_blank" data-smartkarma-citation="accounts:766" rel="noopener">Athaporn Arayasantiparb, CFA</a> takes a look at gaming, specifically related to <a href="https://www.smartkarma.com/entities/advanced-info-service-pcl" target="_blank" data-smartkarma-citation="entities:947:1" rel="noopener">Advanced Info Service (ADVANC TB)</a> and <a href="https://www.smartkarma.com/entities/asiasoft-corp-pcl" target="_blank" data-smartkarma-citation="entities:5429:1" rel="noopener">Asiasoft Corp (AS TB)</a> in Thailand.


Corrigenda: There is an error in this Insight. Please note the correction.
Correction: The Singapore STI Macro Bear Pressure Mounting with Tactical Relief from 2,400 Insight is improperly attributed to Thomas Monaco. That Insight was published by Thomas Schroeder.



The week that was in ASEAN@Smartkarma is filled with another eclectic mix of differentiated, substantive and actionable insights from across South East Asia and includes macro, top-down and thematic pieces, as well as actionable equity bottom-up and credit insights over the past week.
Please find a brief summary below, with a fuller write up in the detailed section. We also include in the detailed section the past week's relevant discussions in ASEAN@Smartkarma.

Equity Bottom-Up Insights
In Kalbe Farma (KLBF IJ) - A Nutritional Spin-Off?, CrossASEAN Insight Provider Angus Mackintosh revisits South East Asia's largest pharmaceutical company in light of news that the company is considering spinning off its Nutritionals division to raise around US$500m. 
In Link Net Tbk Pt (LINK IJ) - Summer Migration at Last, Angus Mackintosh revisits Indonesia's highest quality high-speed broadband provider following a call with managment, which focused on its recent results, as well as the decision to build its own pole infrastructure to carry its fibre.  
In SingTel: Make The Call, David Blennerhassett zeros in on Singapore's leading telecom provider and finds deep value appearing in the stock.
In SCG Packaging IPO Initiation: Shrink Wrapping, Arun George takes a first look at the upcoming spin-off from Siam Cement (SCC TB) and IPO of SCG Packaging, which will get a lot of investor focus given ist size and share in of the packaging market in SE Asia. 
In Sembcorp - Last Chance Before... Travis Lundy looks at the enormously dilutive rights issue and de-merger of Semcorp Marine. 
 In Singapore STI Macro Bear Pressure Mounting with Tactical Relief from 2,400, technical analysis specialist Thomas J. Monaco works his technical magic on the FTSE Straits Times Index (STI) (STI INDEX).
In RATCH: 3Q20 Earnings to Improve from Overseas Performance, our friend at Country Group report back on Ratchaburi Electric (RATCH TB) post its more recent analyst meeting, which left a positive impression.  
In B-WORK: Good Dividend Yield Makes an Attractive Investment, Dr. Andrew Stotz, CFA revisits Bualuang Office Leasehold Real Estate Investment Trust (B-WORK TB) and takes a positive view. 
In RBF: The Excessive Outperformance May Come to a Halt, Dr. Andrew Stotz, CFA upgrades his recommendation on R&amp;B Food Supply PCL (RBF TB) to HOLD from SELL based on raising his target price of THB9.25 from THB8.70, implying a downside of 9% from the current price. 
In STI: Acquisition Benefits Are Not Fully Priced In, Strong BUY, Dr. Andrew Stotz, CFA revisits Stonehenge Inter (STI TB) with a BUY recommendation based on his target of THB10.10, implying an upside of 31% from the current share price. 
In DOD: Strong Performance Deserves a Re-Rating, Dr. Andrew Stotz, CFA upgrades his recommendation on DOD Biotech PCL (DOD TB) to BUY from HOLD based on raising his target price to Bt10.70 from Bt7.55, implying an upside of 26% from the current price. 
In VRANDA: The Calm Before Challenging Times, Dr. Andrew Stotz, CFA has a SELL recommendation on Veranda Resort PCL (VRANDA TB) based on a target price of THB4.30, implying a downside of 26% from the current share price. 
In ACE: Results Are Not Stunning, Stay on HOLD, Dr. Andrew Stotz, CFA upgrades his recommendation on Absolute Clean Energy PCL (ACE TB) to HOLD from SELL based on raising his target price to THB3.49 from THB2.64, implying an upside of 8% from the current price. 
In SPA: Weak Demand Continues to Pressure 2H20 Earnings, Dr. Andrew Stotz, CFA downgrades Siam Wellness Group (SPA TB) from BUY to HOLD rating and cut his target price by 31% to THB6.6 to factor in weakening earnings momentum in 2H20. 
In GUNKUL: New 60MW Power Plant to Drive 2H20 Earnings, Country Group maintain a BUY rating on Gunkul Engineering (GUNKUL TB) with a target price of THB3.24 derived using DCF method (WACC 7.8% and TG 1%) implying 11.4x FY20E PER or 0.5x relative PER to Thai utility sector. 
Sector and Thematic Insights
In Telecom Review (Sept 2020): AIS and AsiaSoft Get Aggressive on Gaming, our Thai guru Athaporn Arayasantiparb, CFA takes a look at gaming, specifically related to Advanced Info Service (ADVANC TB) and Asiasoft Corp (AS TB) in Thailand. 

The Week that Was in ASEAN@Smartkama - Kalbe Spin-Off, SingTel's Deep Value, and Thailand's Gamers

We upgrade our recommendation on DOD to BUY from HOLD based on raising our target price to Bt10.70 from Bt7.55, implying an upside of 26% from the current price. We revise our forecast upward and roll over our target price to the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:
<ul>
<li>Network marketing creates a new sales channel with tremendous growth potential</li>
<li>Recent acquisition expands cosmetics manufacturing capacity</li>
<li>Significant R&amp;D spending necessary to remain competitive</li>
</ul>
Interim: DOD continues to deliver strong results, as 2Q20 has demonstrated. Our previously cautious stance towards future growth prospects has turned more optimistic, based on DOD’s strategy to realize high growth opportunities.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

We upgrade our recommendation on DOD to BUY from HOLD based on raising our target price to Bt10.70 from Bt7.55, implying an upside of 26% from the current price. We revise our forecast upward and roll over our target price to the 2021E PB/ROE of Thai Consumer Staples and apply a 15% small-cap discount.
Investment thesis:

Network marketing creates a new sales channel with tremendous growth potential
Recent acquisition expands cosmetics manufacturing capacity
Significant R&amp;D spending necessary to remain competitive

Interim: DOD continues to deliver strong results, as 2Q20 has demonstrated. Our previously cautious stance towards future growth prospects has turned more optimistic, based on DOD’s strategy to realize high growth opportunities.
Risks: Dependent on a few large clients and intense competition, lack of long-term contracts, inability to collect receivables, non-compliance with health standards, unable to find competent people to fill c-suite positions.

DOD: Strong Performance Deserves a Re-Rating

Thailand

DOD Biotech PCL produces dietary supplements. The Company focuses on manufacturing of capsules, tablets, powder drinks, and other supplements. DOD Biotech also engages in research and development of raw materials and ingredients. DOD Biotech serves customers in Thailand.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DOD Biotech PCL (DOD TB)

DOD: Failed Investment in Cosmetics Requires New Strategy

We maintained a HOLD recommendation on DOD and an unchanged target price of Bt13.30, implying an upside of 2% from the current price.

A. Stotz Investment Research

DOD: Recent Bullish Rally Overestimates Hemp Hype

We change our recommendation to a HOLD from BUY after DOD showed a strong price rally. But we increase our target price to Bt13.30 from Bt10.70,...

A. Stotz Investment Research

DOD: More to Come in Beauty Products and Network Marketing

We keep our BUY recommendation on DOD based on our target price of Bt10.70, implying an upside of 18%. We derive our target price from the 2021E PB...

A. Stotz Investment Research

The Week that Was in ASEAN@Smartkama - Kalbe Spin-Off, SingTel's Deep Value, and Thailand's Gamers

The week that was in ASEAN@Smartkarma is filled with another eclectic mix of differentiated, substantive and actionable insights from across South...

Angus Mackintosh

DOD: Strong Performance Deserves a Re-Rating

We upgrade our recommendation on DOD to BUY from HOLD based on raising our target price to Bt10.70 from Bt7.55, implying an upside of 26%.

A. Stotz Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)